VOR Phase III MG enrollment complete; key readout eyed for early 2027
VOR says enrollment in its Phase III MG trial is complete, with a key readout expected in early 2027. The company also plans an ocular MG study and enhanced dosing convenience.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.